Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics (NCT07481396) | Clinical Trial Compass
RecruitingNot Applicable
Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
South Korea60 participantsStarted 2025-12-01
Plain-language summary
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.
The main question this study aims to answer is:
Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?
To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
* Patients without contraindications for lumbar puncture catheter insertion for cerebrospinal fluid (CSF) collection. This includes the absence of:
* Uncontrolled diabetes.Coagulation disorders.
* Thrombocytopenia (platelet count $\< 100,000).
* A history of cirrhosis diagnosis.
* Current receipt of low molecular weight heparin.
* Current use of platelet inhibitors.
* A history of posterior spinal fusion that may interfere with catheter insertion.
* Local skin infection or rash at the puncture site.
* Signs of systemic infection or sepsis.
* A history of lumbar puncture within the past 6 hours.
Exclusion Criteria:
* Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
* Patients who underwent extracorporeal membrane oxygenation (ECMO).
* Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
* Patients with a history of acute or chronic brain disease.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Neurological outcome
Timeframe: at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)